1. Home
  2. NTNX vs ABVX Comparison

NTNX vs ABVX Comparison

Compare NTNX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutanix Inc.

NTNX

Nutanix Inc.

HOLD

Current Price

$42.01

Market Cap

9.1B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$106.74

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTNX
ABVX
Founded
2009
2013
Country
United States
France
Employees
N/A
67
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
9.7B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
NTNX
ABVX
Price
$42.01
$106.74
Analyst Decision
Buy
Buy
Analyst Count
19
13
Target Price
$62.29
$131.31
AVG Volume (30 Days)
3.1M
773.7K
Earning Date
05-27-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
227.45
N/A
EPS
0.57
N/A
Revenue
$2,537,927,000.00
N/A
Revenue This Year
$13.44
$52.14
Revenue Next Year
$13.03
$4,132.27
P/E Ratio
$72.55
N/A
Revenue Growth
18.11
N/A
52 Week Low
$34.01
$5.59
52 Week High
$83.36
$148.83

Technical Indicators

Market Signals
Indicator
NTNX
ABVX
Relative Strength Index (RSI) 58.48 38.54
Support Level $35.23 $100.33
Resistance Level $42.19 $108.00
Average True Range (ATR) 1.59 5.07
MACD 0.38 -1.34
Stochastic Oscillator 95.24 0.67

Price Performance

Historical Comparison
NTNX
ABVX

About NTNX Nutanix Inc.

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: